Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNS007
MIFTS: 45

Bone Sarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Sarcoma

About this section

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma 12 58 15

Characteristics:

Orphanet epidemiological data:

58
bone sarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:0080639
UMLS via Orphanet 72 C0029463 C1704327
Orphanet 58 ORPHA223727
Sources

Summaries for Bone Sarcoma

About this section
Disease Ontology : 12 A bone cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Bone Sarcoma is related to sarcoma and fibrous histiocytoma. An important gene associated with Bone Sarcoma is CCNB3 (Cyclin B3), and among its related pathways/superpathways are PAK Pathway and Cytokine Signaling in Immune system. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Bone Sarcoma

About this section

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 sarcoma 32.2 TNFRSF1A SRC SERPINA3 MTAP IL6 EWSR1
2 fibrous histiocytoma 31.5 SERPINA3 MTAP EWSR1
3 malignant fibrous histiocytoma 31.5 SERPINA3 MTAP MB EWSR1
4 neutropenia 31.3 TNFRSF1A IL6 IL1RN IL10 CXCL8 CSF3
5 sarcoma, synovial 31.3 SERPINA3 EWSR1 CCNB3 BCOR
6 osteomyelitis 31.1 IL6 IL1RN IL10 CXCL8 CSF3
7 mesenchymal cell neoplasm 30.9 SERPINA3 MIR199A1 EWSR1 CCNB3 BCOR
8 bone cancer 30.9 SERPINA3 MTAP MIR21 MIR199A1 MIR195 KDM4C
9 exanthem 30.9 IL6 IL1RN IL10 CXCL8 CTLA4 CSF3
10 stomatitis 30.8 IL6 IL1RN IL10 CXCL8 CSF3
11 myxofibrosarcoma 30.8 SERPINA3 MTAP EWSR1
12 dedifferentiated liposarcoma 30.8 SERPINA3 MIR100 MB EWSR1
13 severe combined immunodeficiency 30.7 IL6 IL1RN IL10 CSF3 CSF1
14 thrombocytopenia 30.7 TNFRSF1A SRC IL6 IL1RN IL10 CXCL8
15 bone osteosarcoma 30.6 EWSR1 CCNB3 BCOR
16 paracoccidioidomycosis 30.6 IL6 IL10 CTLA4
17 acute cystitis 30.6 SERPINA3 IL6 IL10 CXCL8
18 rhabdomyosarcoma 2 30.6 MB EWSR1 CCNB3 BCOR
19 bone resorption disease 30.6 SERPINA3 MIR199A1 IL6 CSF1
20 synovitis 30.6 TNFRSF1A IL6 IL1RN CXCL8
21 spondylitis 30.5 IL6 IL1RN IL10
22 toxic shock syndrome 30.5 TNFRSF1A IL6 IL1RN IL10 CXCL8
23 bone disease 30.5 SRC SERPINA3 IL6 CXCL8 CSF1
24 osteoporosis 30.3 SRC MIR21 IL6 IL1RN IL10 CXCL8
25 bone inflammation disease 30.2 TNFRSF1A SERPINA3 MIR21 MIR199A1 IL6 IL1RN
26 systemic lupus erythematosus 30.1 TNFRSF1A MIR21 MIR195 IL6 IL1RN IL10
27 pancreatic cancer 29.6 SRC SERPINA3 MIR21 MIR199A1 MIR195 MIR100
28 osteogenic sarcoma 12.0
29 chondrosarcoma 11.5
30 ewing sarcoma 11.5
31 bone giant cell tumor 11.4
32 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
33 li-fraumeni syndrome 11.1
34 enchondromatosis, multiple, ollier type 11.1
35 li-fraumeni syndrome 2 11.1
36 fibrosarcoma of bone 11.1
37 spindle cell sarcoma 10.8
38 acute transverse myelitis 10.8 IL6 IL10 CXCL8
39 transverse myelitis 10.8 IL6 IL10 CXCL8
40 small cell sarcoma 10.8 EWSR1 CCNB3 BCOR
41 bronchiolitis 10.8 IL6 IL10 CXCL8
42 kidney sarcoma 10.8 EWSR1 CCNB3 BCOR
43 small cell osteogenic sarcoma 10.8 EWSR1 CCNB3 BCOR
44 rhabdoid cancer 10.8 KDM4C EWSR1 BCOR
45 post-transplant lymphoproliferative disease 10.8 TNFRSF1A IL6 IL10
46 progressive myoclonus epilepsy 8 10.8 IL6 IL10 CXCL8
47 chlamydia pneumonia 10.8 IL6 IL10 CXCL8
48 chlamydia 10.8 IL6 IL10 CXCL8
49 juvenile arthritis 10.8 IL6 IL10 CXCL8
50 autoimmune disease of eyes, ear, nose and throat 10.8 IL6 IL10 CTLA4

Graphical network of the top 20 diseases related to Bone Sarcoma:



Diseases related to Bone Sarcoma
Sources

Symptoms & Phenotypes for Bone Sarcoma

About this section

MGI Mouse Phenotypes related to Bone Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 BCOR CSF1 CSF3 CTLA4 IL10 IL1RN
2 immune system MP:0005387 9.9 BCOR CSF1 CSF3 CTLA4 IL10 IL1RN
3 integument MP:0010771 9.65 CSF1 CSF3 CTLA4 IL10 IL1RN IL6
4 respiratory system MP:0005388 9.23 CSF1 CTLA4 IL10 IL6 MB MTAP
Sources

Drugs & Therapeutics for Bone Sarcoma

About this section

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
3
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
4
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
5
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
6
nivolumab Approved Phase 1, Phase 2 946414-94-4
7
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
8
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
9
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
10
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
11
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
12
Pembrolizumab Approved Phase 2 1374853-91-4
13
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Ifosfamide Approved Phase 2 3778-73-2 3690
16
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
17
leucovorin Approved Phase 2 58-05-9 6006 143
18
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
19
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
20
Lenograstim Approved, Investigational Phase 2 135968-09-1
21
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
22
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24 Exatecan Investigational Phase 2 171335-80-1
25 interferons Phase 2
26 Interferon-alpha Phase 2
27 Interferon alpha-2 Phase 2
28 Anti-Infective Agents Phase 2
29 Antibodies, Monoclonal Phase 2
30 Antifungal Agents Phase 2
31 Imatinib Mesylate Phase 2 220127-57-1 123596
32 Tubulin Modulators Phase 2
33 Cyclosporins Phase 2
34 Calcineurin Inhibitors Phase 2
35 Angiogenesis Inhibitors Phase 1, Phase 2
36 Pharmaceutical Solutions Phase 1, Phase 2
37 Anti-HIV Agents Phase 2
38 Analgesics Phase 2
39 Interleukin-2 Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Anti-Retroviral Agents Phase 2
42 Immunoglobulins Phase 2
43 Antibodies Phase 2
44 Antineoplastic Agents, Immunological Phase 2
45 Antiviral Agents Phase 2
46 Antioxidants Phase 2
47 Immunologic Factors Phase 2
48 Anti-Bacterial Agents Phase 2
49 Immunosuppressive Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
2 Phaseâ…¡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
3 A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
4 A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas Completed NCT01016015 Phase 2 Temsirolimus
5 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
6 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
9 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
10 Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma Completed NCT00802880 Phase 2 Dacarbazine
11 A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide Completed NCT00267046 Phase 2 Palifermin;Placebo;Adriamycin (Doxorubicin);Ifosfamide;Vincristine;Cisplatin
12 Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas Recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent];Nivolumab 100 MG/10 ML [Opdivo]
13 Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration Recruiting NCT04040205 Phase 2 Abemaciclib
14 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
15 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab
16 Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases Not yet recruiting NCT03965234 Phase 1, Phase 2 Cisplatin
17 A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Suspended NCT03468075 Phase 2 Ascorbate;Gemcitabine
18 A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
19 A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma Terminated NCT02022358 Phase 2 Glucarpidase;Methotrexate;Folinic Acid
20 Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas Terminated NCT00544778 Phase 2 dexrazoxane hydrochloride;doxorubicin hydrochloride;ifosfamide;irinotecan hydrochloride
21 An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma Completed NCT01896505 Phase 1 KCP-330
22 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma Recruiting NCT03462316 Phase 1
23 In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas Recruiting NCT02811523 Phase 1 Doxorubicin
24 A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors Terminated NCT01204450 Phase 1 Temsirolimus;Valproic Acid
25 A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy Terminated NCT01491594 Phase 1 Eltrombopag
26 Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults Unknown status NCT01780779
27 Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity Unknown status NCT01533779
28 Transcultural Validation of MSTS and TESS Questionnaire Unknown status NCT03765970
29 Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients Unknown status NCT02845583
30 Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment Completed NCT00824083
31 A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years Completed NCT02986503 Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
32 Long Term Clinical and Functional Outcome in Patients Operated on Van Ness-Borggreve Rotationplasty for Lower Limnb Bone Tumor Completed NCT03385694
33 Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors Completed NCT00598741
34 A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Recruiting NCT04055220 Treatment by Regorafenib;Treatment by Placebo
35 Pre-Surgical Supervised Exercise for Bone Cancer Patients Recruiting NCT02893397
36 Clinical Evaluation for Sarcoma Originated From Bone Recruiting NCT03358992
37 ICONIC: Improving Outcomes Through Collaboration in OsteosarComa Recruiting NCT04132895
38 Incorporating the Patient Voice in Sarcoma Research: How Can we Assess Health-related Quality of Life in This Heterogeneous Group of Patients? Recruiting NCT04071704
39 Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas Recruiting NCT03442465
40 Observational Study, for Quality Assessment, of Sarcoma as a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK Recruiting NCT04181970
41 Etiosarc: Study of the Environmental Aetiology (Environment, Occupations and Lifestyle) of Sarcomas (Soft Tissue, Visceral and Bone) From a Multicenter French Population-based Case-control Study Among Adults. Recruiting NCT03670927
42 DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study Active, not recruiting NCT00525057 Dalteparin
43 Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone Enrolling by invitation NCT03134742

Search NIH Clinical Center for Bone Sarcoma

Sources

Genetic Tests for Bone Sarcoma

About this section
Sources

Anatomical Context for Bone Sarcoma

About this section

MalaCards organs/tissues related to Bone Sarcoma:

40
Bone, Lung, T Cells, Breast, Brain, Neutrophil, Bone Marrow
Sources

Publications for Bone Sarcoma

About this section

Articles related to Bone Sarcoma:

(show top 50) (show all 821)
# Title Authors PMID Year
1
Surgical and oncological outcomes after hindquarter amputation for pelvic sarcoma. 61
32475235 2020
2
Is Skeletal Imaging Essential in the Staging Workup for Conventional Chondrosarcoma? 61
32567825 2020
3
The utility of 18F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis. 61
32571371 2020
4
The miR-143/145 Cluster, a Novel Diagnostic Biomarker in Chondrosarcoma, Acts as a Tumor Suppressor and Directly Inhibits Fascin-1. 61
32027760 2020
5
The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. 61
31919587 2020
6
Feasibility and Value of Establishing a Community-Based Virtual Multidisciplinary Sarcoma Case Conference. 61
32530806 2020
7
The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma. 61
31900513 2020
8
Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study. 61
32499311 2020
9
Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. 61
32057288 2020
10
Primary bone sarcoma with BCOR internal tandem duplication. 61
31900635 2020
11
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. 61
32129883 2020
12
Anti-osteosarcoma property of decorin-modified titanium surface: A novel strategy to inhibit oncogenic potential of osteosarcoma cells. 61
32187963 2020
13
Leucine and branched-chain amino acid metabolism contribute to the growth of bone sarcomas by regulating AMPK and mTORC1 signaling. 61
32297642 2020
14
Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells. 61
31808569 2020
15
Upregulation of miRNA-154-5p prevents the tumorigenesis of osteosarcoma. 61
32000044 2020
16
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study. 61
32066914 2020
17
Experiences of return to work after treatment for extremital soft tissue or bone sarcoma: Between distraction and leaving the disease behind. 61
32017298 2020
18
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. 61
32326412 2020
19
Assessment of Familiarity With Work-up Guidelines for Bone and Soft Tissue Sarcoma Among Primary Care Practitioners in Minnesota. 61
32280924 2020
20
Tranexamic Acid in Patients With Cancer Undergoing Endoprosthetic Reconstruction: A Retrospective Review. 61
32142488 2020
21
Decision-making in Orthopaedic Oncology: Does Cognitive Bias Affect a Virtual Patient's Choice Between Limb Salvage and Amputation? 61
31173578 2020
22
Cabozantinib: a new perspective for advanced bone sarcoma. 61
32078814 2020
23
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. 61
32004793 2020
24
The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells. 61
31778284 2020
25
Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? 61
32164350 2020
26
Omic approaches to pediatric bone sarcomas. 61
31736201 2020
27
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression. 61
32110934 2020
28
Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control? 61
31863159 2020
29
The association between socioeconomic position and tumour size, grade, stage, and mortality in Danish sarcoma patients - A national, observational study from 2000 to 2013. 61
31702424 2020
30
[Treatment concepts for complications after resection and defect reconstruction of pelvic tumours]. 61
31996946 2020
31
A novel next generation sequencing approach to improve sarcoma diagnosis. 61
32047232 2020
32
Application of Low Doses of Ionizing Radiation in Medical Therapies. 61
31933547 2020
33
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. 61
31969978 2020
34
Time to Treatment Initiation and Survival in Adult Localized High-Grade Bone Sarcoma. 61
32454786 2020
35
Oncological and endoprosthetic outcomes of bone sarcoma patients: a nationwide cohort study. 61
31324968 2020
36
Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children. 61
31948458 2020
37
The long-term results of extendable endoprostheses of the humerus in children after the resection of a bone sarcoma. 61
31888359 2020
38
Pediatric extremity bone sarcoma reconstruction with the vascularized fibula flap: Observational study assessing long-term functional outcomes, complications, and survival. 61
31563475 2019
39
Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. 61
31520938 2019
40
Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. 61
31622129 2019
41
Diagnostic accuracy of primary bone and soft tissue sarcomas by 18-FDG PET: Systematic review and meta-analysis. 61
31887730 2019
42
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. 61
31704134 2019
43
What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors? 61
31764339 2019
44
Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas. 61
31241814 2019
45
Construction of Anti-hPD-L1 HCAb Nb6 and in Situ124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma. 61
31535847 2019
46
Radiotherapy for the Palliation of Advanced Sarcomas-The Effectiveness of Radiotherapy in Providing Symptomatic Improvement for Advanced Sarcomas in a Single Centre Cohort. 61
31635409 2019
47
Ion channels in sarcoma: pathophysiology and treatment options. 61
31377822 2019
48
Factors associated with functional outcome in patients having limb salvage surgery for primary malignant bone sarcoma using TESS. 61
31528081 2019
49
[The importance of radiology in bone sarcoma diagnostics : Initial and advanced diagnostics]. 61
31392388 2019
50
Identifying bone sarcoma survivors facing psychosocial challenges. A study of trajectories following treatment. 61
31184795 2019
Sources

Variations for Bone Sarcoma

About this section
Sources

Expression for Bone Sarcoma

About this section
Search GEO for disease gene expression data for Bone Sarcoma.
Sources

Pathways for Bone Sarcoma

About this section

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PAK Pathway 63
Show member pathways
 13.17 TNFRSF1A SRC IL6 IL10 CXCL8 CSF3
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.14 TNFRSF1A SRC IL6 IL1RN IL10 CXCL8
3
Pathogenic Escherichia coli infection 36
12.11 TNFRSF1A SRC IL6 CXCL8
4
Tuberculosis 36
12.07 TNFRSF1A SRC IL6 IL10
5
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.99 IL6 IL1RN IL10 CXCL8
6
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 11.99 TNFRSF1A IL6 IL10 CXCL8 CSF1
7
Yersinia infection 36
11.78 SRC IL6 IL10 CXCL8
8
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.73 IL6 IL10 CSF3 CSF1
9
Pertussis 36
11.64 IL6 IL10 CXCL8
10
Dendritic Cells Developmental Lineage Pathway 64
11.62 IL6 IL10 CSF1
11
Rheumatoid arthritis 36
11.59 IL6 CXCL8 CTLA4 CSF1
12
LPA receptor mediated events 1
11.56 SRC IL6 CXCL8
13
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.52 TNFRSF1A IL6 CXCL8
14
Lung fibrosis 1
11.51 IL6 CXCL8 CSF3
15
Hematopoietic Stem Cell Differentiation 1
11.35 IL6 CSF3 CSF1
16
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.3 SRC IL6 CXCL8
17
Malaria 36
11.16 IL6 IL10 CXCL8 CSF3
18
Interleukin-10 signaling 65
10.86 TNFRSF1A IL6 IL1RN IL10 CXCL8 CSF3
19
Cytokines and Inflammatory Response 1
10.72 IL6 IL10 CSF3 CSF1
Sources

GO Terms for Bone Sarcoma

About this section

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNFRSF1A SERPINA3 MIR21 MIR199A1 MIR100 IL6

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 SRC MIR21 KDM4C IL6 CSF1
2 negative regulation of cell proliferation GO:0008285 9.89 MIR21 MIR195 IL6 IL10 CXCL8
3 positive regulation of apoptotic process GO:0043065 9.8 SRC MIR21 MIR195 IL6 CTLA4
4 immune response GO:0006955 9.8 IL6 IL1RN IL10 CXCL8 CTLA4 CSF3
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 SRC MIR21 CSF3
6 positive regulation of protein kinase B signaling GO:0051897 9.73 SRC MIR21 MIR199A1 CSF3
7 inflammatory response GO:0006954 9.73 TNFRSF1A SERPINA3 IL6 IL1RN CXCL8 CSF1
8 response to glucocorticoid GO:0051384 9.65 IL6 IL1RN IL10
9 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.55 MIR195 IL10
10 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.54 IL1RN IL10
11 positive regulation of cytokine secretion GO:0050715 9.54 SRC MIR21 IL10
12 response to molecule of bacterial origin GO:0002237 9.52 IL10 CXCL8
13 negative regulation of regulatory T cell differentiation GO:0045590 9.46 MIR21 CTLA4
14 cellular response to lipopolysaccharide GO:0071222 9.43 SRC MIR21 IL6 IL10 CXCL8 CSF3
15 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.33 MIR21 IL6 IL1RN
16 cytokine-mediated signaling pathway GO:0019221 9.17 TNFRSF1A IL6 IL1RN IL10 CXCL8 CSF3

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL6 IL10 CSF3 CSF1
2 cytokine activity GO:0005125 9.1 IL6 IL1RN IL10 CXCL8 CSF3 CSF1
Sources

Sources for Bone Sarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....